Buzz on rare disease drugs puts ViroPharma in the M&A spotlight

John Carroll

's pipeline of for diseases has reportedly stirred the interest of several pharma companies. And once word of the buyout spread the Exton, PA-based biotech's shares zoomed up 9% yesterday afternoon.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS